Electromed Inc (ELMD) 4.68 $ELMD
Electromed posts record USD6m dollar quarter, with 180% rise in operating income
M2 - Wed Feb 10, 6:17AM CST
Airway clearance system company Electromed (NYSE MKT:ELMD) disclosed on Tuesday that its operating income was USD1.25m for the three month period ended 31 December 2015.
ELMD: 4.68 (-0.31)
Electromed, Inc. Reports Record $6 Million Dollar Quarter
Business Wire - Tue Feb 09, 3:30PM CST
Electromed, Inc. (NYSE MKT: ELMD) today announced financial results for the three- and six-month periods ended December 31, 2015.
ELMD: 4.68 (-0.31)
Electromed, Inc. to Present at the Southwest IDEAS Investor Conference on November 19th in Dallas
Business Wire - Wed Nov 11, 2:02PM CST
Electromed, Inc. (ELMD), today announced that Kathleen Skarvan, President and CEO and Jeremy Brock, CFO, will present at the Southwest IDEAS Investor Conference on Thursday November 19, 2015 at the Marriott - Quorum Hotel in Dallas, Texas. Electromed, Inc. Company's presentation is scheduled to begin at 3:10 pm Central. The presentation will be webcast live and may be accessed at the conference website, www.IDEASConferences.com, or in the investor relations section of the company's website: http://www.smartvest.com.
ELMD: 4.68 (-0.31)
Electromed, Inc. Reports Higher First Quarter Revenues and Operating Income
Business Wire - Tue Nov 10, 3:30PM CST
Electromed, Inc. (NYSE MKT:ELMD) today announced financial results for its first quarter ended September 30, 2015.
ELMD: 4.68 (-0.31)
Electromed posts lower Q4 net income of USD255,000
M2 - Wed Sep 16, 6:18AM CDT
Airway clearance therapy company Electromed (NYSE MKT:ELMD) stated on Tuesday its net income of USD255,000 (USD0.03 per basic and diluted share) for its fourth quarter of fiscal year ending 30 June 2015.
ELMD: 4.68 (-0.31)
Electromed, Inc. Reports Higher Fourth Quarter and Full Year Revenues and Profits
Business Wire - Tue Sep 15, 3:30PM CDT
--Full Year Earnings per Share $0.13 Compared to Loss of $0.16 in Prior Year
ELMD: 4.68 (-0.31)
The Zacks Analyst Blog Highlights: Virco Mfg., Electromed and Willdan Group - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Virco Mfg., Electromed and Willdan Group
VIRC: 3.15 (-0.02), WLDN: 8.71 (+0.27), ELMD: 4.68 (-0.31)
Forget Greece, Buy These Small-Cap Value Stocks Instead - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 01, 10:12AM CDT
Greece became the first developed economy in the world to default on a loan early Wednesday. Amid the intense equity market volatility, small cap stocks remain the ideal choice to tide over the storm.
VIRC: 3.15 (-0.02), WLDN: 8.71 (+0.27), ELMD: 4.68 (-0.31)
Edwards Lifesciences' Sapien 3 Heart Valve Wins FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 18, 1:20PM CDT
The FDA approval reinforces Edwards' (EW) commitment toward transforming high-risk aortic stenosis treatment.
MDT: 75.61 (+0.69), EW: 87.36 (+0.24), CPHD: 33.43 (+0.78), ELMD: 4.68 (-0.31)
Cyberonics (CYBX) Q4 Earnings Top, Sorin Deal in Progress - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 05, 8:35AM CDT
Cyberonics (CYBX) reported mixed fourth-quarter fiscal 2015 results, wherein the bottom line exceeded the Zacks Consensus Estimate, while the top line missed the same
CPHD: 33.43 (+0.78), ELMD: 4.68 (-0.31), CYBX: 69.95 (+0.86)
FDA Okays Cyberonics AspireSR Generator for Epilepsy Cure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 03, 1:50PM CDT
Cyberonics' (CYBX) AspireSR generator constitutes an additional feature: automatic stimulation in response to detection of a seizure in drug-resistant epileptic patients.
CPHD: 33.43 (+0.78), ELMD: 4.68 (-0.31), CYBX: 69.95 (+0.86)
Is Edwards Lifesciences (EW) Worth Adding to Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 03, 1:30PM CDT
Edwards (EW) expects to expand the availability of transcatheter technology and double sales of global TAVR procedures to more than $3 billion in 2019.
EW: 87.36 (+0.24), CPHD: 33.43 (+0.78), ELMD: 4.68 (-0.31)
Is Electromed an Incredible Value Stock? 3 Reasons Why ELMD Will Be Tough to Beat - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 27, 7:54AM CDT
Electromed is a great value stock to watch out for from the new Zacks style score perspective
ELMD: 4.68 (-0.31)
How Healthy Does Healthcare Look: Complementary Research on Health Insurance, Ardelyx, Electromed, CAS Medical and Capnia
PR Newswire - Mon May 18, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
HIIQ: 6.22 (+0.27), CASM: 1.61 (+0.02), ARDX: 9.14 (-0.92), CAPN: 1.20 (+0.02), ELMD: 4.68 (-0.31)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed May 13, 11:45AM CDT
ZBRA: 65.41 (-1.10), EBR: 1.79 (+0.07), XNET: 5.71 (-0.09), VTAE: 4.69 (-5.11), SSRI: 6.69 (+0.21), PER: 2.85 (+0.22), RENT: 44.47 (-1.04), OHGI: 0.94 (-0.01), DSKX: 1.56 (+0.04), INUV: 2.03 (-0.01), NSTG: 15.43 (+0.03), DCO: 15.07 (-0.26), XENE: 7.22 (-0.24), BPTH: 1.59 (-0.26), RMD: 57.85 (+0.42), ATV: 5.71 (-0.21), GWGH: 6.50 (-0.41), SBLK: 0.92 (+0.14), DSCO: 2.02 (-0.02), ELMD: 4.68 (-0.31)
Electromed beats on revenue
Seeking Alpha - at Seeking Alpha - Tue May 12, 4:19PM CDT
ELMD: 4.68 (-0.31)
Electromed, Inc. Reports Higher Third Quarter Revenues and Profits
Business Wire - Tue May 12, 3:30PM CDT
Electromed, Inc. (NYSE MKT: ELMD) today announced financial results for the three- and nine-month periods ended March 31, 2015. Net revenues for the third quarter of fiscal 2015 rose approximately 15% to $4.56 million, compared to $3.96 million in the same quarter of fiscal 2014. The Company reported net income of $37,000, or $0.00 cents per basic and diluted share, for the third quarter of fiscal 2015, compared to a net loss of $1,004,000, or ($0.12) per basic and diluted share, for the same period of fiscal 2014.
ELMD: 4.68 (-0.31)
Cepheid: Q1 Impresses, Non-Clinical Business Turns Around - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 28, 9:14AM CDT
Interestingly, Cepheid's (CPHD) Non-Clinical business returned to positive top-line growth during the quarter.
ABC: 88.00 (-0.22), INGN: 33.06 (+0.07), CPHD: 33.43 (+0.78), ELMD: 4.68 (-0.31)
Cepheid's (CPHD) Xpert HIV-1 Qual Test Gets CE-IVD Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 3:13PM CDT
Cepheid recently received CE-IVD approval (under the European Directive on In Vitro Diagnostic Medical Devices) for its Xpert HIV-1 Qual.
ABMD: 84.00 (+0.94), CPHD: 33.43 (+0.78), LMNX: 19.75 (+0.08), ELMD: 4.68 (-0.31)
Qiagen Grows on Molecular Diagnostics, Americas Disappoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 2:32PM CDT
On Apr 17, 2015, we issued an updated research report on Qiagen N.V. (QGEN).
ABMD: 84.00 (+0.94), LMNX: 19.75 (+0.08), QGEN: 22.27 (+0.07), ELMD: 4.68 (-0.31)
Electromed posts record USD6m dollar quarter, with 180% rise in operating income
M2 - Wed Feb 10, 6:17AM CST
Airway clearance system company Electromed (NYSE MKT:ELMD) disclosed on Tuesday that its operating income was USD1.25m for the three month period ended 31 December 2015.
ELMD: 4.68 (-0.31)
Electromed, Inc. Reports Record $6 Million Dollar Quarter
Business Wire - Tue Feb 09, 3:30PM CST
Electromed, Inc. (NYSE MKT: ELMD) today announced financial results for the three- and six-month periods ended December 31, 2015.
ELMD: 4.68 (-0.31)
Electromed, Inc. to Present at the Southwest IDEAS Investor Conference on November 19th in Dallas
Business Wire - Wed Nov 11, 2:02PM CST
Electromed, Inc. (ELMD), today announced that Kathleen Skarvan, President and CEO and Jeremy Brock, CFO, will present at the Southwest IDEAS Investor Conference on Thursday November 19, 2015 at the Marriott - Quorum Hotel in Dallas, Texas. Electromed, Inc. Company's presentation is scheduled to begin at 3:10 pm Central. The presentation will be webcast live and may be accessed at the conference website, www.IDEASConferences.com, or in the investor relations section of the company's website: http://www.smartvest.com.
ELMD: 4.68 (-0.31)
Electromed, Inc. Reports Higher First Quarter Revenues and Operating Income
Business Wire - Tue Nov 10, 3:30PM CST
Electromed, Inc. (NYSE MKT:ELMD) today announced financial results for its first quarter ended September 30, 2015.
ELMD: 4.68 (-0.31)
Electromed posts lower Q4 net income of USD255,000
M2 - Wed Sep 16, 6:18AM CDT
Airway clearance therapy company Electromed (NYSE MKT:ELMD) stated on Tuesday its net income of USD255,000 (USD0.03 per basic and diluted share) for its fourth quarter of fiscal year ending 30 June 2015.
ELMD: 4.68 (-0.31)
Electromed, Inc. Reports Higher Fourth Quarter and Full Year Revenues and Profits
Business Wire - Tue Sep 15, 3:30PM CDT
--Full Year Earnings per Share $0.13 Compared to Loss of $0.16 in Prior Year
ELMD: 4.68 (-0.31)
The Zacks Analyst Blog Highlights: Virco Mfg., Electromed and Willdan Group - Press Releases
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Virco Mfg., Electromed and Willdan Group
VIRC: 3.15 (-0.02), WLDN: 8.71 (+0.27), ELMD: 4.68 (-0.31)
Forget Greece, Buy These Small-Cap Value Stocks Instead - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 01, 10:12AM CDT
Greece became the first developed economy in the world to default on a loan early Wednesday. Amid the intense equity market volatility, small cap stocks remain the ideal choice to tide over the storm.
VIRC: 3.15 (-0.02), WLDN: 8.71 (+0.27), ELMD: 4.68 (-0.31)
Edwards Lifesciences' Sapien 3 Heart Valve Wins FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 18, 1:20PM CDT
The FDA approval reinforces Edwards' (EW) commitment toward transforming high-risk aortic stenosis treatment.
MDT: 75.61 (+0.69), EW: 87.36 (+0.24), CPHD: 33.43 (+0.78), ELMD: 4.68 (-0.31)
Cyberonics (CYBX) Q4 Earnings Top, Sorin Deal in Progress - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 05, 8:35AM CDT
Cyberonics (CYBX) reported mixed fourth-quarter fiscal 2015 results, wherein the bottom line exceeded the Zacks Consensus Estimate, while the top line missed the same
CPHD: 33.43 (+0.78), ELMD: 4.68 (-0.31), CYBX: 69.95 (+0.86)
FDA Okays Cyberonics AspireSR Generator for Epilepsy Cure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 03, 1:50PM CDT
Cyberonics' (CYBX) AspireSR generator constitutes an additional feature: automatic stimulation in response to detection of a seizure in drug-resistant epileptic patients.
CPHD: 33.43 (+0.78), ELMD: 4.68 (-0.31), CYBX: 69.95 (+0.86)
Is Edwards Lifesciences (EW) Worth Adding to Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 03, 1:30PM CDT
Edwards (EW) expects to expand the availability of transcatheter technology and double sales of global TAVR procedures to more than $3 billion in 2019.
EW: 87.36 (+0.24), CPHD: 33.43 (+0.78), ELMD: 4.68 (-0.31)
Is Electromed an Incredible Value Stock? 3 Reasons Why ELMD Will Be Tough to Beat - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 27, 7:54AM CDT
Electromed is a great value stock to watch out for from the new Zacks style score perspective
ELMD: 4.68 (-0.31)
How Healthy Does Healthcare Look: Complementary Research on Health Insurance, Ardelyx, Electromed, CAS Medical and Capnia
PR Newswire - Mon May 18, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
HIIQ: 6.22 (+0.27), CASM: 1.61 (+0.02), ARDX: 9.14 (-0.92), CAPN: 1.20 (+0.02), ELMD: 4.68 (-0.31)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed May 13, 11:45AM CDT
ZBRA: 65.41 (-1.10), EBR: 1.79 (+0.07), XNET: 5.71 (-0.09), VTAE: 4.69 (-5.11), SSRI: 6.69 (+0.21), PER: 2.85 (+0.22), RENT: 44.47 (-1.04), OHGI: 0.94 (-0.01), DSKX: 1.56 (+0.04), INUV: 2.03 (-0.01), NSTG: 15.43 (+0.03), DCO: 15.07 (-0.26), XENE: 7.22 (-0.24), BPTH: 1.59 (-0.26), RMD: 57.85 (+0.42), ATV: 5.71 (-0.21), GWGH: 6.50 (-0.41), SBLK: 0.92 (+0.14), DSCO: 2.02 (-0.02), ELMD: 4.68 (-0.31)
Electromed beats on revenue
Seeking Alpha - at Seeking Alpha - Tue May 12, 4:19PM CDT
ELMD: 4.68 (-0.31)
Electromed, Inc. Reports Higher Third Quarter Revenues and Profits
Business Wire - Tue May 12, 3:30PM CDT
Electromed, Inc. (NYSE MKT: ELMD) today announced financial results for the three- and nine-month periods ended March 31, 2015. Net revenues for the third quarter of fiscal 2015 rose approximately 15% to $4.56 million, compared to $3.96 million in the same quarter of fiscal 2014. The Company reported net income of $37,000, or $0.00 cents per basic and diluted share, for the third quarter of fiscal 2015, compared to a net loss of $1,004,000, or ($0.12) per basic and diluted share, for the same period of fiscal 2014.
ELMD: 4.68 (-0.31)
Cepheid: Q1 Impresses, Non-Clinical Business Turns Around - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 28, 9:14AM CDT
Interestingly, Cepheid's (CPHD) Non-Clinical business returned to positive top-line growth during the quarter.
ABC: 88.00 (-0.22), INGN: 33.06 (+0.07), CPHD: 33.43 (+0.78), ELMD: 4.68 (-0.31)
Cepheid's (CPHD) Xpert HIV-1 Qual Test Gets CE-IVD Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 3:13PM CDT
Cepheid recently received CE-IVD approval (under the European Directive on In Vitro Diagnostic Medical Devices) for its Xpert HIV-1 Qual.
ABMD: 84.00 (+0.94), CPHD: 33.43 (+0.78), LMNX: 19.75 (+0.08), ELMD: 4.68 (-0.31)
Qiagen Grows on Molecular Diagnostics, Americas Disappoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 2:32PM CDT
On Apr 17, 2015, we issued an updated research report on Qiagen N.V. (QGEN).
ABMD: 84.00 (+0.94), LMNX: 19.75 (+0.08), QGEN: 22.27 (+0.07), ELMD: 4.68 (-0.31)
